How MDA-supported research to counteract a complement protein and rev up regulatory T cells may improve MG treatment
posted on April 1, 2014 - 9:27am
"I’m on CellCept, prednisone, Mestinon and IVIG every three weeks," says 38-year-old Rachel Pegram. "Prednisone, which I have taken for more than 22 years now, has very rough side effects. It has caused weight gain, diabetes and glaucoma. I cannot say I have ever gone into remission without drugs, but I believe I have been in a drug-induced remission. I have spent a lot of time in hospitals for...
Jacobus Pharmaceutical has opened its original, 30-person, invitation-only trial of 3,4-diaminopyridine for Lambert-Eaton myasthenic syndrome (LEMS) to additional participants who meet study criteria
posted on October 1, 2013 - 5:00am
Update (April 14, 2014): This phase 2 trial of 3,4-diaminopyridine is now closed to new participants. However, the drug remains available on a "compassionate use" -- also called "expanded access" -- basis to qualified patients with LEMS and related disorders of the neuromuscular junction. See Treatment Use of 3,4-Diaminopyridine; or enter NCT01765140 in the search box at ClinicalTrials.gov.
University of Illinois-Chicago scientist receives $530,480 to test immune system modulator for myasthenia gravis
posted on March 14, 2011 - 3:51pm
Update (June 10, 2013): In 2013, Matthew Meriggioli relocated from the University of Illinois to the Novartis Institutes for BioMedical Research in Cambridge, Mass. The laboratory work on GM-CSF has been completed, and Meriggioli and other investigators are looking at the possibility of starting the clinical trial at an alternative site.